Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care

Circulation: Cardiovascular Genetics

Volumn 6, Issue 4, 2013, Pages 400-408

  DeGorter, Marianne K ^a   Tirona, Rommel G ^a   Schwarz, Ute I ^a   Choi, Yun Hee ^a   Dresser, George K ^a   Suskin, Neville ^a   Myers, Kathryn ^a   Zou, Guang Yong ^a   Iwuchukwu, Otito ^c   Wei, Wei Qi ^c   Wilke, Russell A ^c   Hegele, Robert A ^a,b   Kim, Richard B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ATP binding cassette transporters; Hydroxymethylglutaryl CoA reductase inhibitors; Organic anion transporters; Pharmacogenetics; Pharmacokinetics; Sodium independent

Indexed keywords

4 BETA HYDROXYCHOLESTEROL; ALANINE; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL; CYSTEINE; LATHOSTEROL; ORGANIC ANION TRANSPORTER 2; ROSUVASTATIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DATA BASE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ATP-BINDING CASSETTE TRANSPORTERS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACOGENETICS; PHARMACOKINETICS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; FEMALE; FLUOROBENZENES; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 84884507686     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000099     Document Type: Article

References (40)

1. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult -2009 recommendations. Can J Cardiol. 2009;25:567-579.
2. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and lowdensity lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208-1215.
3. US Department of Health and Human Services. Health, United States, 2010, with special feature on death and dying. 2011. http://www.cdc.gov/nchs/hus.html. Accessed October 29, 2012.
4. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy -A genomewide study. N Engl J Med. 2008;359:789-799.
5. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858-868.
6. Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97:69C-76C.
7. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414.
8. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87:130-133.
9. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249-273.
10. Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, Pulley JM, et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet. 2010;86:560-572.
11. DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB. Disposition of atorvastatin, rosuvastatin, and simvastatin in Oatp1b2-/-mice and intraindividual variability in human subjects. J Clin Pharmacol. 2012;9:986-995.
12. Honda A, Yamashita K, Hara T, Ikegami T, Miyazaki T, Shirai M, et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res. 2009;50:350-357.
13. Honda A, Yamashita K, Miyazaki H, Shirai M, Ikegami T, Xu G, et al. Highly sensitive analysis of sterol profiles in human serum by LC-ESIMS/MS. J Lipid Res. 2008;49:2063-2073.
14. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. http://www.R-project.org. Accessed January 14, 2012.
15. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.
16. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev. 2008;40:317-354.
17. Zaïr ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics. 2008; 9:597-624.
18. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-And African-Americans. J Biol Chem. 2001;276:35669- 35675.
19. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726-733.
20. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873-879.
21. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al. Effect of drug transporter genotypes on pravastatin disposition in European-And African-American participants. Pharmacogenet Genomics. 2007;17:647-656.
22. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005;78:342-350.
23. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5:257-264.
24. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330-341.
25. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86:197-203.
26. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010;87:558-562.
27. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, et al SPACE ROCKET Trial Group. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010;3:276-285.
28. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem. 2001;276:38685-38689.
29. Diczfalusy U, Nylén H, Elander P, Bertilsson L. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol. 2011;71:183-189.
30. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25:2553-2563.
31. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15:415-421.
32. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov. 2005;4:911-918.
33. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011;365:285-287.
34. Thompson PD, Clarkson P, Karas RH. Statin-Associated myopathy. JAMA. 2003;289:1681-1690.
35. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol. 1996;36:242-246.
36. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMGCoA reductase inhibitor. J Clin Pharmacol. 2002;42:1116-1121.
37. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-1155.
38. De Cuyper I, Wolthers BG, van Doormaal JJ, Wijnandts PN. Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis. Clin Chim Acta. 1993;219:123-130.
39. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-1948.
40. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92:112-117.